动脉粥样硬化（atherosclerosis, AS）是多种免疫细胞（如巨噬细胞、T细胞）和细胞因子参与的自身免疫病，其中Th17及IL-17具有促进AS形成的作用，因此，研究Th17/IL-17通路在AS中的作用有可能获得更大的治疗益处，干预该通路的研究成为防治AS领域研究的新热点。前期临床研究表明，补肾抗衰片治疗动脉粥样硬化性疾病疗效肯定，预实验提示，其可能通过下调T-bet、IFN-γ减少Th1的表达，下调RORγt、IL-17减少Th17在AS模型中的表达起到抗AS的效应。本研究以免疫机制为切入点，通过离体和在体实验，用补肾抗衰片进行干预，在干预靶点的多环节、检测的多水平、干预的多时点上，明确Th17与AS的相关性、动态观察Th17/IL-17通路在AS形成、发展过程中的作用，进而阐明补肾抗衰片治疗AS的分子机制，为进一步深入揭示补肾抗衰片的药理作用及其起效靶点的确认提供科学依据。

Atherosclerosis (AS) is an autoimmune disease, a variety of immune cells (eg macrophages, T cells) and cytokines involved this diseases of hanpen and the development. Th17 and IL-17 have the effect of promotes atherosclerosis. So, the study of role of Th17 / IL-17 pathways is likely to gain greater treatment benefits, interve in this pathway, may be the new hot topics in the study of prevention and treatment atherosclerosis. Preliminary studies show that BuShenKangShuai tablets has the function cure atherosclerosis by cutting T-bet, IFN-gamma reduce Th1 expression, cutting ROR-gamma T, IL-17 reduce Th17 expression in the AS model.This study use BuShenKangShuai tablets as drug intervention, immunologic mechanism use an entry point, by in vitro and in vivo experiments, detection target is many link, detection method is more level, intervention time is multiple, to clear the correlation between Th17 and atherosclerosis, to dynamic observe the role of Th17/IL-17 pathways in atherosclerosis, to clarify the molecular mechanism of BuShenKangShuai tablets treatment atherosclerosis, reveal its pharmacological effects, and provide a scientific basis for confirmation.